title: A single centre's experience of stereotactic radiosurgery and radiotherapy for non-functioning pituitary adenomas with the Linear Accelerator (Linac).
abstract: Non-functioning pituitary adenomas are primarily a surgically managed pathology, but recurrence or regrowth is not uncommon. Previous large series have retrospectively validated the use of the Gamma Knife (GK) as an adjuvant treatment. To our knowledge, we present the largest case series to date with the Linear Accelerator (Linac) for the management of this pathology. In this study we review the clinical course of 118 patients, 51 of whom had stereotactic radiosurgery (SRS) and 67 who had fractionated stereotactic radiotherapy (FSRT); the discriminatory feature being proximity to the optic chiasm. For comparison purposes a population of 53 patients who had conventional radiotherapy (CRT) is included. The local control rates at 5 years for SRS, FRST and CRT were 100%, 93% and 87% respectively. Treatment-related morbidity was low. These data confirm that Linac SRS and FSRT are safe and effective for the treatment of non-functioning pituitary adenomas.
authors.affiliation: Department of Neurosurgery, Wollongong Hospital, Wollongong, New South Wales, Australia.
authors.forename: P J
authors.initials: PJ
authors.lastname: Wilson
authors.forename: K J
authors.initials: KJ
authors.lastname: De-Loyde
authors.forename: J R
authors.initials: JR
authors.lastname: Williams
authors.forename: R I
authors.initials: RI
authors.lastname: Smee
mesh_terms: D000236:Adenoma / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D018572:Disease-Free Survival; D023381:Endpoint Determination; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010315:Particle Accelerators; D010911:Pituitary Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D016634:Radiosurgery / Q000009:adverse effects / Q000379:methods*; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult